Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients (Q39175584)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 November 2016

Language	Label	Description	Also known as
English	Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients	scientific article published on 8 November 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

phase II clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Motoki Miyazawa

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Masahiro Katsuda

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Hiroyuki Maguchi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Akio Katanuma

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Hiroshi Ishii

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Masato Ozaka

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Kenji Yamao

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Manabu Kawai

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Seiko Hirono

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ken-Ichi Okada

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Hiroki Yamaue

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

0 references

publication date

8 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

140

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

973-982

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Neoantigens in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Kinesin family member 20A is a novel melanoma-associated antigen

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30510

21 January 2018

Identifiers

10.1002/IJC.30510

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27861852%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39175584&oldid=1811878433"